Brief: Bio-Rad Q3 Adjusted EPS USD 2.01 Vs. IBES Estimate USD 1.16
30/10/2024 20:15
Oct 30 (Reuters) - Bio-Rad Q3 EPS USD 23.34. * Q3 gross margin 54.8% * Q3 EBIT margin 9.9% * Q3 net income USD 653.2 million * Q3 sales USD 649.7 million vs. IBES estimate USD 628.2 million
Recent news on Bio-Rad Laboratories
See all newsBio-Rad Laboratories, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Bio-Rad Laboratories On July 31, Initiated Restructuring Plan - SEC Filing
Bio-Rad Q2 revenue beats analyst estimates on clinical diagnostics growth
Brief: Bio-Rad Q2 Net Income USD 371.4 Million
Activist investors make bigger push for campaigns in H1, seek more M&A